 Oyster Point Pharma, Inc. OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced positive top-line results from the Phase 3 ONSET-2 study in dry eye disease. The ONSET-2 trial met the primary endpoint, where a greater percentage of subjects treated with 0.6 mgml and 1.2 mgml of OC-01 gained 10 mm on Schirmers score, a measure of tear film production, compared to control. 